A phase 2, single-center, randomized, double-blind, placebo-controlled study in patients with longstanding T1D demonstrated that rapamycin restored Treg function and reduced insulin requirements in vivo [84] (Table 1, Figure 2). This evidence concerns the gene INS and type 1 diabetes mellitus.